Hints and tips:
...Gleevec, Novartis’ pill for chronic myeloid leukaemia, is one example. Since its approval in 2001, Gleevec has brought in revenues of $42bn....
...Novartis, the Swiss group, has long operated a patient assistance programme in several dozen countries including India, for Glivec, its treatment for chronic myeloid leukaemia....
...Examples include: ● A gene change called Bcr-Abl is found in most chronic myeloid leukaemias. Patients who test positive are likely to respond to Glivec from Novartis....
...The verdict is seen as having wide implications not just for Glivec – used to treat chronic myeloid leukaemia – but other medicines that multinational drug companies want to patent in India....
...Glivec has provided a cure for many patients with chronic myeloid leukaemia; Rituxin and Herceptin have substantially boosted survival rates for other cancers....
...Oncology sales also rose 13 per cent, to $1.5bn, on 20 per cent growth from Gleevec/Glivec, used to treat chronic myeloid leukaemia....
...myeloid leukaemia discovered and sold by Novartis as Gleevec....
International Edition